Tortugas Neuroscience, Inc.

Tortugas Neuroscience, Inc. , based in the U. S. , is dedicated to developing innovative therapies aimed at addressing complex brain disorders and enhancing brain health through advanced scientific discoveries.

Tortugas Neuroscience, Inc. specializes in creating therapies for various neurological conditions. The company was founded in Framingham, US, and has raised a total of USD 106 mn through Seed and Series A funding rounds. The most recent deal took place on April 21, 2026, led by Cure Ventures along with new investors The Column Group and AN Ventures Partners.

The founder's details are not available. Tortugas Neuroscience focuses on the development of innovative therapies targeting brain disorders, which include a range of clinical assets aimed at neurological and neuropsychiatric conditions. Their pipeline features products like TRTL-107, TRTL-913, TRTL-729, and TRTL-118, designed to serve healthcare providers, research institutions, and pharmaceutical partners across North America and Europe. Tortugas Neuroscience generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions, engaging in business-to-business transactions that support the development and commercialization of clinical assets.

Revenue sources include milestone payments, licensing agreements, and potential royalties upon commercial success, negotiated through strategic contracts. In April 2026, Tortugas Neuroscience plans to advance its research and development, particularly focusing on the completion of its Phase 2 trials. The company aims to launch its new products targeting specific neurological challenges while expanding its market reach into Europe. The recent Series A funding will support these initiatives, facilitating the continued development of their therapeutic pipeline.